CompletedPhase 3NCT02207621

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Studying NON RARE IN EUROPE: Primary adult open-angle glaucoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aerie Pharmaceuticals
Principal Investigator
Theresa Heah, MD
Aerie Pharmaceuticals, Inc.
Intervention
AR-13324 Ophthalmic Solution 0.02%(drug)
Enrollment
756 target
Eligibility
99 years · All sexes
Timeline
20142016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02207621 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma

← Back to all trials